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Effects of Weight Reduction, Exercise, and Diet Modification on Lipids 
and Apolipoproteins A-l and B in Severely Obese Persons* 
J. David Fachnie, MD^ and Craig C. Foreback, FhD^ 
We assessed the lipid and apolipoprotein effects of hypocaloric dieting, increased physical activity, 
and dietary modification in severely overweight adults (body mass index [BMI] 43.05 kg/m-). The 34 
women and four men enrolled in the ambulatory weight control program donated blood before, 
during, and after hypocaloric dieting (420 kcal/day). 
Mean values before dieting included cholesterol of223 mg/dL, high-density lipoprotein (HDL) 
cholesterol of 43 mg/dL, and cholesterol/HDL cholesterol of 5.90. This placed our subjects at high 
risk for coronary artery disease. Other values included triglycerides of 138 mg/dL, apolipoprotein A-l 
of 152 mg/dL. and apolipoprotein B/apolipoprotein A-l of 0.64. Significant reductions during 
hypocaloric dieting included mean cholesterol of 171 mg/dL, triglycerides of 99 mg/dL. and 
apolipoprotein A-l of 120 mg/dL. During weight maintenance (mean BMI 36.08 kg/m^). significant 
reductions compared to baseline included a mean cholesterol of204 mg/dL and cholesterol/HDL 
cholesterol of 4.60. Also, a significant increase occurred in HDL cholesterol (51 mg/dL). but a 
nonsignificant elevation was observed in apolipoprotein A-l (180 mg/dL). In four subjects, discordant 
ratios of cholesterol/HDL cholesterol or apolipoprotein B/apolipoprotein A-1 were seen. and one ratio 
improved in two subjects despite relapse of obesity. Changes in both HDL composition and HDL 
particle concentration may explain elevations of HDL cholesterol and apolipoprotein A-l after 
dieting. Discordance between lipid and apolipoprotein ratios may occur. Improvement in lipids or 
apolipoproteins may be seen despite regained weight. (Henry FordHosp MedJ 1987:35:216-20) 
Data from the National Health and Nutrition Examination Surveys (1,2) show that obese persons are more apt to have 
hypertension, diabetes mellitus, or hypercholesterolemia (1). 
Even children who are more obese have higher levels of the ad-
verse lipids, low-density lipoprotein (LDL) cholesterol and tri-
glycerides, and lower levels of the favorable lipids, high-density 
lipoprotein (HDL) cholesterol (2). The association of obesity 
with dyslipidemias, diabetes mellitus, and hypertension may be 
responsible for an increased risk of coronary artery disease 
(CAD) in obese adults (3). 
An important question is to what extent will obese persons 
who attain a stable, lower weight manifest reduction in these risk 
factors? The effects of dietary weight reduction upon the dys-
lipidemia of the obese have been studied in 282 subjects of di-
verse degrees of adiposity, under various dietary regimes, and 
using several different measures of lipoprotein metabolism 
(4-15). 
The stability of changes in lipoproteins is most important 
from the standpoint of whether reduced CAD risk may be ob-
tained. A smaller number of obese persons (112) had their lipids 
evaluated after they attained a stable, lower weight (6-9,11-15). 
Measurement of apolipoproteins (Apo) A- l and B, the major 
protein components of high- and low-density lipoproteins, re-
spectively, is fundamental to better understand the effects of 
weight reduction on lipoprotein physiology. However, only one 
report has included Apo A-l and B measurements in long-term 
follow-up (II). This report describes our experience in measur-
ing semm lipids and Apo A-l and B in a group of severely over-
weight adults who attended an ambulatory intensive weight 
reduction program. The objective was to assess the effects of 
acute weight loss brought on by a very low calorie diet (VLCD). 
Later, the same measures were repeated when the subjects were 
on a weight maintenance diet after a stable, lower weight had 
been achieved. 
Experimental Subjects 
The original patient population consisted of predominantly 
white, middle-class adults who were severely overweight (I)' 
The subjects recmited included 34 women (aged 25 to 60 years, 
mean 42 years) and four men (aged 32 to 50 years, mean 42 
years). They agreed to follow the program and to donate blood 
specimens as necessary to monitor the metabolic effects of 
weight reduction. Of the women, all except three were prS' 
menopausal, four were on estrogen or progesterone prepara' 
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Table 1 
Weight and Body Mass Index at Baseline, 
Phase 2, and Phase 3* 
Table 2 
Serum Lipids and Apolipoproteins Before, During, 
and After Acute Weight Loss* 
Baseline Phase 2 Phase 3 
Weigh' (kg) 
Body ffl^ss index 
(Icg/m-) 
Weeks 
kgj2!L 
116.38 (88-191) 103.04(171-165) 94.76(74-127) 
43.05 (35-55) 37.88 (29-56) 
8.76 (2-16) 
13.34 
36.08 (30-51) 
33.04 (12-88) 
21.62 
•Numbers are means with ranges in parentheses. 
tions, and six were on a thiazide diuretic or beta blocker before 
dieting. Of the men, two were on a thiazide diuretic before diet-
ing. Thiazide diuretics were discontinued in all patients after 
dietary treatment began. 
Materials and Methods 
After a detailed history, physical examination, electrocar-
diogram, and Minnesota Multiphasic Personality Inventory, 
fasting semm was obtained and assayed for triglyceride, choles-
terol, and HDL cholesterol using standard methods (16-18). 
Total semm Apo A-l and B were assayed with a commercial as-
say by ligand combined with nephilometry (19,20). All subjects 
met the criteria for need and safety of a VLCD. The VLCD is 
defined as less than 800 kcal/day. All subjects signed an in-
formed consent that outlined potential hazards and the need to 
comply rigidly with our instmctions. 
Dietary intervention occurred in three phases. Phase 1 was a 
1,000 to 1,200 kcal/day balanced-deficit diet that lasted two to 
three weeks. Phase 2 was a VLCD diet including 420 kcal/day, 
70 g protein, 30 g carbohydrate, 2 g fat, and vitamin and mineral 
supplementation (Optifast 70®, Sandoz Corporation, NY). The 
phase 2 diet was to be continued for 16 weeks or unril goal 
weight was achieved. Goal weight was defined by the subject 
and physician as being a desirable and achievable weight, typ-
ically 10% to 20% over ideal body weight. Phase 3 was a 1,000 
to 1,200 kcal/day balanced-deficit diet (20% protein, 50% car-
bohydrate, 30% fat with a P/S ratio of 1) that resulted in weight 
maintenance at the termination of rapid weight loss (phase 2). 
Blood specimens were obtained at baseline, at the termination of 
phase 2, and during weight maintenance (phase 3). Phase 3 
blood was drawn when the subject was eating 1,000 or more 
kcal/day and had not lost weight for two or more weeks. 
Several subjects had difficulty adhering strictly to this dietary 
program. Therefore, only baseline and phase 2 data are available 
for 12 subjects. Some subjects intermpted phase 2 for a variable 
time and then returned. Others continued the dietary therapy, 
without hiatus, for up to 36 weeks. In addition to dietary ther-
apy, all subjects received a series of weekly lectures and support 
sessions to enhance compliance, to educate about healthy and 
unhealthy eating behaviors, and to encourage exercise in the 
form of walking 20 to 30 minutes three or more times weekly. 
Fasting semm was obtained in most subjects during phases 2 and 
3. Several subjects donated blood six or more hours after their 
last meal rather than in the fasting state. 
Statistical analysis included calculation of mean, range, and 
standard deviation. With paired t tests, comparisons were made 
''etween baseline to phase 2, baseline to phase 3, and phase 2 to 
Baseline Phase 2 Phase 3 
Cholesterol 223(37)t 171 (27)t 204 (26)t 
Triglycerides 138 (29) 99 (22)t 114(18) 
HDL Cholesterol 43 (19) 41(8) 51 (14)t 
Apo A-I 152(17) 120(10)* 180(12) 
ApoB 95(17) 61(9) 98 (11) 
Cholesterol/ 
HDL Cholesterol 5.90(17) 4.95 (9) 4.60 (12)t 
Apo B/Apo A-I 0.64(17) 0.52 (9) 0.56(11) 
*A1I values are expressed as the mean in mg/dL. 
tNumber in parentheses indicates number of subjects. 
tP < 0.017 for baseline to phase 2 or baseline to phase 3. 
phase 3. The Bonferroni method was used to minimize the 
chance of incorrectly claiming significance, and the P-value was 
set for groups of three tests at 0.017 and for two tests at 0.025. 
Results 
Weight data, reviewed in Table 1, showed a severely over-
weight sample of subjects, mean BMI 43.05 kg/m}. During 
rapid weight reduction (phase 2), a mean of 13.34 kg was lost 
over an 8.76-week period before phase 2 blood was drawn. 
When weight maintenance was achieved (phase 3), an average of 
21.62 kg had been lost over a mean of 33.04 weeks. 
Baseline lipid and apolipoprotein data for all subjects are 
listed in Table 2. Mean cholesterol was over the 75th percentile 
for both men and women, according to Lipid Research Clinics' 
normative data (21). Mean HDL cholesterol was within two stan-
dard deviations of Lipid Research Clinics' norms, but was below 
ideal for both men and women according to Framingham norms 
of 55 mg/dL for women and 45 mg/dL for men (22). A very high 
percentage of the women (6/17 [35%]) had HDL cholesterol val-
ues below 37 mg/dL (34 mg/dL is the fifth percentile). Mean 
choIesteroI/HDL cholesterol of 5.90 placed our subjects in the 
same category as men with CAD (mean 5.8) or women with 
CAD (mean 5.3) (23). No normative data exist for Apo A-l and 
B measurements. However, the mean Apo A- l of 152 mg/dL 
would not be considered depressed, and thus increasing the 
CAD risk, when compared to men with CAD or female relatives 
of men with CAD (24,25). Likewise, the mean Apo B of 95 mg/ 
dL was not elevated, and so indicative of increased CAD risk, 
compared to available comparison data with female relatives of 
CAD victims or putatively high-risk women with noninsulin-
dependent diabetes mellitus (25,26). 
The effect of a VLCD and a lower, stable weight on the same 
measures is also summarized in Table 2. Statistical analysis 
using paired t tests permitted comparison of changes in mean 
response from baseline to phase 2, baseline to phase 3, and 
phase 2 to phase 3. The VLCD (baseline versus phase 2) was 
associated with significant reductions in cholesterol, triglycer-
ides, and Apo A - l . Statistically insignificant reductions were 
seen in Apo B, cholesterol/HDL cholesterol, and Apo B/Apo 
A-l . A stable, lower weight (baseline versus phase 3) was asso-
ciated with statistically significant reductions in cholesterol and 
cholesterol/HDL cholesterol. A statistically significant increase 
was seen in HDL cholesterol. 
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Figure—Changes in cholesterol/HDL cholesterol and apo-
lipoprotein B/apolipoprotein A-l. (a = P<0.017.) 
Comparison of the cholesterol/HDL cholesterol ratio to that 
of Apo B/Apo A- l revealed corresponding reductions in both 
during the VLCD (phase 2) (Figure). These reductions obtained 
statistical significance for cholesterol/HDL cholesterol only 
during weight maintenance (phase 3). 
Review of individual values of cholesterol/HDL cholesterol 
and Apo B/Apo A- l before and after a stable, usually lower, 
weight had been achieved (baseline versus phase 3) showed that 
one or both ratios fell in most subjects (9/12 [75%]) (data not 
shown). In subjects 1 and 2, substantial weight reduction was 
associated with reductions in cholesterol/HDL cholesterol while 
Apo B/Apo A-l increased (Table 3). In subjects 3 and 4, choles-
terol/HDL cholesterol increased and Apo B/Apo A-l decreased 
after weight reduction. In subject 4, reductions in Apo B/Apo 
A-l occurred even though she regained weight and increased her 
ratio of cholesterol/HDL cholesterol. In subject 5, a reduction in 
cholesterol/HDL cholesterol was observed although all the 
weight lost had been regained. 
Discussion 
The dyslipidemia of a group of severely overweight, middle-
class Americans and the effect of both rapid weight reduction 
with a VLCD and maintenance of a lower weight upon this dys-
lipidemia have been described. In addition to diet, the therapy 
included behavior change instmction to encourage more healthy 
eating behaviors and moderate exercise. Most subjects were 
very sedentary before the program, but a majority reported the 
equivalent of 20 minutes of walking three or more times weekly 
by the period of weight maintenance. Also, most subjects were 
eating a diet high in fat and calories before the program, but di-
etary interviews revealed efforts to restrict fat and total calories 
by the time they had entered weight maintenance. Because of 
the complex changes that occurred in subjects' weight, physical 
activity, and the composition of the diet, our results must be in-
terpreted as the consequence of all these changes, rather than 
loss of body weight per se. 
At baseline, semm lipid values suggested that the sample as a 
whole may have a higher-than-average CAD risk. The mean 
cholesterol of 223 mg/dL was over the 75th percentile by Lipid 
Research Clinics' norms (21), and would warrant dietary treat-
ment according to the Consensus Conference on Lowering 
Blood Cholesterol (27). The mean HDL cholesterol of 43 mg/dL 
placed both our women and men subjects at increased CAD risk 
according to Framingham data (22), and 35% of the women had 
HDL cholesterol values below 37 mg/dL (the fifth percentile is 
34 mg/dL) (21). The mean cholesterol/HDL cholesterol ratio of 
5.90 corresponded to studies of men and women subjects who 
have CAD (23). 
During rapid weight reduction, significant drops were ob-
served in mean cholesterol (223 to 171 mg/dL or 23%) and tri-
glycerides (138 to 99 mg/dL or 28%) without a corresponding 
drop in HDL cholesterol. Significant reductions in cholesterol 
and LDL cholesterol have been frequently reported immediately 
after a period of hypocaloric diet-induced weight loss (2,4,8, 
11,14,15). Only two studies have reported VLDL and LDL 
concentrations of triglycerides and cholesterol after acute 
weight reduction. Wolf and Gmndy (14) described a significant 
reduction in cholesterol and VLDL cholesterol, but not LDL 
cholesterol. Avogaro et al (4) described reduction in VLDL, 
LDL, and total cholesterol. Therefore, without direct measures 
we cannot specify whether reductions in VLDL or LDL choles-
terol, or both, contributed to the dramatic reduction in choles-
terol. Significant reductions in triglycerides have also been 
frequently reported immediately after a period of hypocaloric 
diet-induced weight loss (2,4,13-15). The reduction in triglycer-
ides could be due to increased adipose tissue lipoprotein lipase 
activity (28), perhaps associated with a reduction in VLDL tri-
glyceride synthesis (29). Reduction in cholesterol may be re-
lated to a reduction of dietary fat and cholesterol on the VLCD 
(30). Reduced cholesterol and LDL cholesterol may then be a 
consequence of increased hepatic LDL receptors (31). 
Table 3 
Cholesterol/HDL Cholesterol Apo B/Apo A-1 Body Mass Index (kg/m^) 
Subject (Age/Sex) Baseline Phase 3 Baseline Phase 3 Baseline Phase 3 
1 (52/F) 3.17 3.00 0.36 0.38 39 31 
2 (32/M) 6.58 4.20 0.25 0.50 55 35 
3 (58/F) 2.86 2.98 0.46 0.30 51 41 
4 (49/F) 4.02 4.31 0.75 0.50 38 37 
5 (25/F) 7.20 4.49 43 43 
Phase 3 means after rapid weight reduction. 
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During rapid weight reduction, a significant drop was also ob-
efved in Apo A-l (152 to 120 mg/dL or 21%), but nonsignificant 
jeductions occurred in Apo B (95 to 61 mg/dL or 36%) and in the 
ratio of Apo A-l/Apo B (0.64 to 0.52 or 19%). The reduction in 
Apo A-l - the major protein component of HDL, occurred with-
out a corresponding reduction in HDL cholesterol. This sug-
gests that HDL particles may have increased their carriage of 
cholesterol. Two prior studies have shown an increase in both 
y^ po A-1 and HDL cholesterol during or immediately after hy-
pocaloric diet-induced weight loss (4,11). By contrast, Apo B, 
the major protein component of LDL, and cholesterol both fell 
in our subjects. This observation is consistent with prior obser-
vations of the acute effects of hypocaloric dieting on Apo B and 
cholesterol. During weight maintenance at a lower weight, cho-
lesterol, triglyceride, and HDL cholesterol rose from their 
nadirs during the weight loss phase. Cholesterol remained sig-
nificantly lower than baseline (223 to 204 mg/dL or 9% lower). 
Tiiglycerides were not significantly lower than baseline (139 to 
114 mg/dL or 17% lower). HDL cholesterol rose significantly 
over baseline (43 to 51 mg/dL or 19% higher). Reductions in 
cholesterol after weight loss have frequentiy been reported, but 
statistical significance, compared to baseline, has only been re-
ported once before (8). Triglycerides also commonly fall, but 
significance has been achieved in only three reports (12,14,15). 
HDL cholesterol elevation, to a similar, significant degree, has 
been more commonly reported (6-9,11,12,14). 
We obtained reports of increased physical activity and dietary 
reductions in total and saturated fat, compared to baseline. 
These factors may have acted in concert with weight reduction to 
elevate HDL cholesterol in our subjects. In obese, sedentary 
men, increased physical activity or weight loss has been shown 
to increase HDL cholesterol (32). In hypercholesterolemic men, 
reduction in total and saturated fat has been associated with in-
creased HDL cholesterol (33). We did not observe an inverse 
relationship between triglycerides and HDL cholesterol during 
weight reduction. Others have shown that elevations of HDL 
cholesterol with weight reduction in the obese are independent 
of triglycerides (6). The elevation of both HDL cholesterol and 
Apo A-l during refeeding suggests that HDL particle concentra-
tion may increase after hypocaloric dieting in the obese. 
During weight maintenance at a lower weight, Apo A-l and B 
rose from their nadirs to levels not significantly different from 
baseline levels. Nonetheless, a more favorable apolipoprotein 
profile was suggested by the increase in Apo A- l , baseline 152, 
to phase 3, 180 mg/dL or 18% higher, and reduction in the ratio 
of Apo B/Apo A-1, baseline 0.64, to phase 3,0.56 or 13% lower 
Sorbis et al (11) described a significant elevation of Apo A-l two 
to three weeks after a five-week period of weight loss. We are 
aware of no similar reports and conclude that available data sup-
port a modest increase in Apo A-l levels after a stable, lower 
Weight has been obtained in obese persons. 
Ratios of cholesterol/HDL cholesterol and the like are use-
fel in assessing risk for CAD (23). Two studies have shown 
fet apolipoproteins may be even more useful (24,34). In four 
objects, we observed discrepancies between cholesterol/HDL 
(Cholesterol and Apo B/Apo A - l . For the same subjects, the cho-
'esterol/HDL cholesterol ratio fell when Apo B/Apo A-l rose or 
c^e versa. Which ratio should we believe, and how should we 
''enry Ford Hosp Med J—Vol 35, No 4, 1987 
counsel our patients? More data are needed about the effects of 
risk factor intervention on both lipids and apolipoproteins. 
Measures of lipoprotein metabolism during hypocaloric diet-
ing may support a clinical impression that the patient is comply-
ing with the dietary regimen. However, these measures are not 
stable and may not correspond to values obtained after a lower 
weight has been achieved and maintained. The present data have 
shown reductions in cholesterol, increases in HDL cholesterol, 
and reductions in the ratio of cholesterol/HDL cholesterol after a 
stable, lower weight had been achieved. These favorable 
changes should argue well for our subjects' CAD risk if they per-
sist over time. Two of our subjects showed improvement in the 
ratios of cholesterol/HDL cholesterol or Apo B/Apo A-l despite 
their having regained most of the weight lost. If this last observa-
tion can be confirmed, a more favorable outlook in terms of 
CAD risk may be expected for the obese person who retums to 
weight reduction therapy even after repeated failures to keep the 
weight off. 
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